Targeting Drug Effects in IPF
In the first two parts of our blog series on drug delivery in idiopathic pulmonary fibrosis (IPF), we focused on…
Christmas 2020 roundup from the TherapeutAix team
As 2020 draws to a close, the team at TheraeutAix has been looking back and reflecting on the last 12…
Challenges in inhaled drug therapy
In the first blog of this series1, we highlighted that, despite the potential advantages, there appear to be only a…
Drug Development in IPF
Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib,…
Targeted Delivery in IPF: Inhalation Therapy
As part of a four-part series, we are looking at targeted delivery in idiopathic pulmonary fibrosis (IPF). This week, we…
